Results 151 to 160 of about 4,441,099 (286)

READER\'S RESPONSE TOWARD ARCHITECTURE BY ZBIGNIEW HERBERT [PDF]

open access: yes, 2013
READER\'S RESPONSE TOWARD ARCHITECTURE BY ZBIGNIEW HERBERT
S.S., M.Hum., Retnowati,   +1 more
core  

Reader Response: Gender Representation Among Physician Authors of Practice Guidelines Developed, Endorsed, or Affirmed by the American Academy of Neurology. [PDF]

open access: yesNeurology, 2023
Pringsheim T   +10 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

The Art in Writing: Analysis of Two Different Types of Writing Samples

open access: yesWOW Stories, 2013
For the past two years, the author has been exploring the use of global literature in her classroom and ways to help her students read and understand the meanings artists (illustrators) embed in their art to support and enhance the story.
Jenna Loomis
doaj  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Colorado reader: Colorado fires!

open access: yes, 2003
Colorado Reader, Fire, soil & water issue. February 2003.Last year in Colorado, more than 1,400 fires burned 370,000 acres. Several years of drought made 2002 one of our state’s worst fire years.
Jorda, Carrie, author   +3 more
core  

Home - About - Disclaimer - Privacy